<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214421</url>
  </required_header>
  <id_info>
    <org_study_id>156-08-271</org_study_id>
    <secondary_id>2010-018401-10</secondary_id>
    <nct_id>NCT01214421</nct_id>
  </id_info>
  <brief_title>Tolvaptan Extension Study in Participants With ADPKD</brief_title>
  <acronym>TEMPO 4/4</acronym>
  <official_title>Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate whether tolvaptan modifies ADPKD progression as measured by changes from&#xD;
      Baseline (from Study 156-04-251) in total kidney volume (TKV) and renal function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 26, 2010</start_date>
  <completion_date type="Actual">February 29, 2016</completion_date>
  <primary_completion_date type="Actual">February 29, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From the Baseline in Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)</measure>
    <time_frame>Study Baseline (Prior to Day 1 in Study 156-04-251) to Month 24 in this study (Study 156-08-271)</time_frame>
    <description>Total kidney volume is a measure of disease progression in the ADPKD participants. Kidney volume was assessed in T1-weighted magnetic resonance images collected at each study site and sent to a central reviewing facility. At the central reviewing facility, radiologists used proprietary software to measure the volume of both kidneys in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). The percent change in the volume of both kidneys combined was analysed using mixed-effect model repeated measures (MMRM) analysis and reported. This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From the Baseline in Estimated Glomerular Filtration Rate (eGFR) as Assessed by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)</measure>
    <time_frame>Study Baseline (Prior to Day 1 in Study 156-04-251) to Month 24 in this study (Study 156-08-271)</time_frame>
    <description>Estimated Glomerular Filtration Rate (eGFR) according to CKD-EPI is calculated using the CKD-EPI equation, expressed as a single equation, is GFR = 141 × min (serum creatinine [Scr]/κ, 1)α × max(Scr/κ, 1)^-1.209 × 0.993 Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1 in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in eGFR for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). MMRM was used for the analysis. This outcome measure was analyzed only in the participants enrolled from the previous - 156-04-251, as pre-specified in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Slope of Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in Study 156-08-271</measure>
    <time_frame>Study Baseline (Prior to Day 1 in Study 156-08-271) to Month 24 in this study (Study 156-08-271)</time_frame>
    <description>Annualized slope of TKV is a measure of renal function and disease progression in ADPKD participants. The annualized slope is calculated as percentage of growth in TKV (measured in mL by MRI) divided by each participant's years of participation for all participants was calculated using MMRM analysis in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing annualized slope of TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Slope of eGFR (CKD-EPI) for Study 156-04-251 Participants Enrolled in Study 156-08-271</measure>
    <time_frame>Study Baseline (Prior to Day 1 in Study 156-08-271) to Month 24 (Study 156-08-271)</time_frame>
    <description>Annualized slope of eGFR (CKD-EPI) is a measure of renal function and disease progression in ADPKD participants. The annualized slope of eGFR (CKD-EPI) (divided by each participant's years of participation) for all participants was calculated using MMRM analysis in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). eGFR was calculated using the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula. This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized TKV Slope for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271</measure>
    <time_frame>Tolvaptan, Delayed Treated: Baseline to Month 24 in Study 156-08-271; Placebo: Baseline to Month 36 in Study 156-04-251</time_frame>
    <description>Annualized slope of TKV is a measure of renal function and disease progression in ADPKD participants. The annualized slope is calculated as percentage of growth in TKV (measured in mL by MRI) divided by each participant's years of participation, using MMRM analysis to compare annualized slope of TKV for the participants who received placebo in previous study (156-04-251) to annualized slope of TKV for the same participants who received tolvaptan in this study (156-08-271). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251 and who received placebo in the previous study, as pre-specified in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Slope of Renal Function (eGFRCKD-EPI) for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271</measure>
    <time_frame>Tolvaptan, Delayed Treated: Baseline to Month 24 in Study 156-08-271; Placebo: Baseline to Month 36 in Study 156-04-251</time_frame>
    <description>Annualized slope of eGFR (CKD-EPI) is a measure of renal function and disease progression in ADPKD participants. The annualized slope of eGFR (calculated using CKD-EPI formula) divided by each participant's years of participation, using MMRM analysis to compare annualized slope of eGFR (CKD-EPI) for the participants who received placebo in previous study (156-04-251) to the annualized slope of eGFR (CKD-EPI) for the same participants who received tolvaptan in this study (156-08-271). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251 who received placebo in previous study and received tolvaptan in this study, as pre-specified in the protocol.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1083</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease (ADPKD)</condition>
  <arm_group>
    <arm_group_label>Tolvaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 milligrams (mg) in the morning [AM]/15 mg in the evening [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily until the last participant originating from prior studies (either 156-04-251 or 156-04-250, 156-06-260, 156-09-284, 156-09-285, and 156-09-290) who was eligible for efficacy analysis completed the Month 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>Tablets of 15 or 30 mg</description>
    <arm_group_label>Tolvaptan</arm_group_label>
    <other_name>OPC-41061</other_name>
    <other_name>Jinarc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Participants who had successfully completed a Phase 1, 2, or 3 tolvaptan ADPKD or renal&#xD;
        impairment study, with a confirmed diagnosis of ADPKD from prior studies [either 156-04-251&#xD;
        (NCT00428948) or 156-04-250 (NCT00413777), 156-06-260, 156-09-284 (NCT01336972), 156-09-285&#xD;
        (NCT01210560), and 156-09-290 (NCT01451827)].&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants unable to provide written informed consent.&#xD;
&#xD;
          -  Participants (men or women) would not adhere to the reproductive precautions as&#xD;
             outlined in the Informed Consent Form.&#xD;
&#xD;
          -  Participants (women only) with a positive urine pregnancy test.&#xD;
&#xD;
          -  Participants who were pregnant or breast-feeding.&#xD;
&#xD;
          -  Participants unable to take oral medications.&#xD;
&#xD;
          -  Participants who had allergic reactions to tolvaptan or chemically related structures&#xD;
             such as benzazepines (benzazepril, conivaptan, fenoldopam mesylate, or mirtazapine).&#xD;
&#xD;
          -  Participants with disorders in thirst recognition or an inability to access fluids.&#xD;
&#xD;
          -  Participants with critical electrolyte imbalances, as determined by the investigator&#xD;
&#xD;
          -  Participants with or at risk of significant hypovolemia, as determined by&#xD;
             investigator.&#xD;
&#xD;
          -  Participants with significant anemia, as determined by investigator.&#xD;
&#xD;
          -  Participants with a history of substance abuse (within the last 3 years).&#xD;
&#xD;
          -  Participants who were taking other experimental (that is, non-marketed) therapies or&#xD;
             were participating in another clinical drug or device study; participating in the&#xD;
             off-drug follow-up period of another ADPKD trial with tolvaptan was permitted.&#xD;
&#xD;
          -  Participants unable to complete magnetic resonance imaging (MRI) assessments (for&#xD;
             example, participants with ferro-magnetic prostheses, aneurysm clips, severe&#xD;
             claustrophobia).&#xD;
&#xD;
          -  Participants who had taken a vasopressin antagonist (outside of previous participation&#xD;
             in a tolvaptan study).&#xD;
&#xD;
          -  Participants unable to comply with anti-hypertensive or other important medical&#xD;
             therapy.&#xD;
&#xD;
          -  Participants with advanced diabetes.&#xD;
&#xD;
          -  Participants who were taking medications or had an illness that could confound&#xD;
             endpoint assessments (including taking approved therapies for the purpose of affecting&#xD;
             polycystic kidney disease [PKD] cysts).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>C.a.b.a.</city>
        <state>Buenos Aires</state>
        <zip>C1429BWN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Pilar</city>
        <state>Buenos Aires</state>
        <zip>B1629ODT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425APQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Córdoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Caen Cedex</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Lyon Cedex 3</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Reims Cedex</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Saint-Etienne Cedex 2</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Toulouse Cedex 09</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Nurnberg</city>
        <zip>90471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Ciechanów</city>
        <zip>06-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>010731</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Iasi</city>
        <zip>700504</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Inverness</city>
        <zip>IV2 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Investigational Site</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 26, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2010</study_first_posted>
  <results_first_submitted>September 27, 2021</results_first_submitted>
  <results_first_submitted_qc>September 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2021</results_first_posted>
  <disposition_first_submitted>March 2, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 23, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 27, 2017</disposition_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Disease</keyword>
  <keyword>ADPKD</keyword>
  <keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
  <keyword>Adult Polycystic Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthrogryposis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available after marketing approval in global markets or beginning 1-3 years following article publication. There is no end date to the availability of the data.</ipd_time_frame>
    <ipd_access_criteria>Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/</ipd_access_criteria>
    <ipd_url>https://clinical-trials.otsuka.com</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 106 sites in 13 countries from 26 May 2010 to 29 Feb 2016. Eligible participants with autosomal dominant polycystic kidney disease (ADPKD) or renal impairment who completed previous tolvaptan treatment in studies: 156-04-251 (NCT00428948), 156-04-250 (NCT00413777), 156-06-260, 156-09-284 (NCT01336972), 156-09-285 (NCT01210560), and 156-09-290 (NCT01451827) were enrolled in this open-label study.</recruitment_details>
      <pre_assignment_details>All enrolled participants received tolvaptan in this study. Data in this study was collected and reported as per the prior treatment received - tolvaptan (called as early treated) or placebo (called as delayed treated), for study 156-04-251 and all other studies combined.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated)</title>
          <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 milligram (mg) in the morning [AM]/15 mg in the evening [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with tolvaptan in previous Study 156-04-251, hence called as Early Treated.</description>
        </group>
        <group group_id="P2">
          <title>Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated)</title>
          <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with placebo in the previous Study 156-04-251, hence called as Delayed Treated.</description>
        </group>
        <group group_id="P3">
          <title>Tolvaptan (From Other Studies: Tolvaptan, Early Treated)</title>
          <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with tolvaptan in other studies (156-04-250, 156-06-260, 156-09-284, 156-09-285, and 156-09-290), hence called as Early Treated.</description>
        </group>
        <group group_id="P4">
          <title>Tolvaptan (From Other Studies: Placebo, Delayed Treated)</title>
          <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with placebo in other studies (156-04-250, 156-06-260, 156-09-284, 156-09-285, and 156-09-290), hence called as Delayed Treated.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="557"/>
                <participants group_id="P2" count="314"/>
                <participants group_id="P3" count="181"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="507"/>
                <participants group_id="P2" count="256"/>
                <participants group_id="P3" count="143"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Discontinued Site</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal Criteria Met</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The enrolled sample consisted of all participants who were enrolled in this open-label study.</population>
      <group_list>
        <group group_id="B1">
          <title>Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated)</title>
          <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with tolvaptan in previous Study 156-04-251, hence called as Early Treated.</description>
        </group>
        <group group_id="B2">
          <title>Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated)</title>
          <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with placebo in the previous Study 156-04-251, hence called as Delayed Treated.</description>
        </group>
        <group group_id="B3">
          <title>Tolvaptan (From Other Studies: Tolvaptan, Early Treated)</title>
          <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with tolvaptan in other studies (156-04-250, 156-06-260, 156-09-284, 156-09-285, and 156-09-290), hence called as Early Treated.</description>
        </group>
        <group group_id="B4">
          <title>Tolvaptan (From Other Studies: Placebo, Delayed Treated)</title>
          <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with placebo in other studies (156-04-250, 156-06-260, 156-09-284, 156-09-285, and 156-09-290), hence called as Delayed Treated.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="557"/>
            <count group_id="B2" value="314"/>
            <count group_id="B3" value="181"/>
            <count group_id="B4" value="31"/>
            <count group_id="B5" value="1083"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="6.9"/>
                    <measurement group_id="B2" value="42.5" spread="7.2"/>
                    <measurement group_id="B3" value="40.0" spread="10.1"/>
                    <measurement group_id="B4" value="35.6" spread="8.7"/>
                    <measurement group_id="B5" value="41.7" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="516"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="303"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="471"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="172"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="919"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="535"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="169"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="1033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From the Baseline in Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)</title>
        <description>Total kidney volume is a measure of disease progression in the ADPKD participants. Kidney volume was assessed in T1-weighted magnetic resonance images collected at each study site and sent to a central reviewing facility. At the central reviewing facility, radiologists used proprietary software to measure the volume of both kidneys in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). The percent change in the volume of both kidneys combined was analysed using mixed-effect model repeated measures (MMRM) analysis and reported. This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.</description>
        <time_frame>Study Baseline (Prior to Day 1 in Study 156-04-251) to Month 24 in this study (Study 156-08-271)</time_frame>
        <population>The Efficacy Sample consisted of all enrolled participants who took at least 1 dose of study drug and completed 3 years of study drug treatment in previous Study 156-04-251. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan)</title>
            <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with tolvaptan in Study 156-04-251.</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo)</title>
            <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with placebo in Study 156-04-251.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From the Baseline in Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)</title>
          <description>Total kidney volume is a measure of disease progression in the ADPKD participants. Kidney volume was assessed in T1-weighted magnetic resonance images collected at each study site and sent to a central reviewing facility. At the central reviewing facility, radiologists used proprietary software to measure the volume of both kidneys in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). The percent change in the volume of both kidneys combined was analysed using mixed-effect model repeated measures (MMRM) analysis and reported. This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.</description>
          <population>The Efficacy Sample consisted of all enrolled participants who took at least 1 dose of study drug and completed 3 years of study drug treatment in previous Study 156-04-251. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="505"/>
                <count group_id="O2" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.66" spread="26.14"/>
                    <measurement group_id="O2" value="30.58" spread="27.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.358</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of geometric means (final values)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <other_analysis_desc>Derived from the least squares (LS) mean difference between the treatment groups at each visit using MMRM model with factors of treatment, visit, region, baseline, baseline hypertensive status, baseline renal volume status, baseline creatinine clearance status, interaction of treatment and visit, and interaction of baseline and visit.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From the Baseline in Estimated Glomerular Filtration Rate (eGFR) as Assessed by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)</title>
        <description>Estimated Glomerular Filtration Rate (eGFR) according to CKD-EPI is calculated using the CKD-EPI equation, expressed as a single equation, is GFR = 141 × min (serum creatinine [Scr]/κ, 1)α × max(Scr/κ, 1)^-1.209 × 0.993 Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1 in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in eGFR for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). MMRM was used for the analysis. This outcome measure was analyzed only in the participants enrolled from the previous - 156-04-251, as pre-specified in the protocol.</description>
        <time_frame>Study Baseline (Prior to Day 1 in Study 156-04-251) to Month 24 in this study (Study 156-08-271)</time_frame>
        <population>The Efficacy Sample consisted of all enrolled participants who took at least 1 dose of study drug and completed 3 years of study drug treatment in previous Study 156-04-251. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan)</title>
            <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with tolvaptan in Study 156-04-251.</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo)</title>
            <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with placebo in Study 156-04-251.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From the Baseline in Estimated Glomerular Filtration Rate (eGFR) as Assessed by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) for Study 156-04-251 Participants Enrolled in This Study (156-08-271)</title>
          <description>Estimated Glomerular Filtration Rate (eGFR) according to CKD-EPI is calculated using the CKD-EPI equation, expressed as a single equation, is GFR = 141 × min (serum creatinine [Scr]/κ, 1)α × max(Scr/κ, 1)^-1.209 × 0.993 Age × 1.018 (if female) × 1.159 (if black), where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/ĸ or 1, and max indicates the maximum of Scr/κ or 1 in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in eGFR for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). MMRM was used for the analysis. This outcome measure was analyzed only in the participants enrolled from the previous - 156-04-251, as pre-specified in the protocol.</description>
          <population>The Efficacy Sample consisted of all enrolled participants who took at least 1 dose of study drug and completed 3 years of study drug treatment in previous Study 156-04-251. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>mL/min/1.73 square meters (m^2)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.77" spread="13.16"/>
                    <measurement group_id="O2" value="-19.92" spread="16.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference (final values)</param_type>
            <param_value>3.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.462</ci_lower_limit>
            <ci_upper_limit>4.836</ci_upper_limit>
            <other_analysis_desc>Derived from MMRM analysis with fixed factors of treatment, visit, treatment visit interaction, hypertensive status, renal volume status and creatinine clearance status at baseline, region, baseline value, and baseline visit interaction as covariates, and with a heterogeneous toeplitz variance covariance matrix.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Slope of Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in Study 156-08-271</title>
        <description>Annualized slope of TKV is a measure of renal function and disease progression in ADPKD participants. The annualized slope is calculated as percentage of growth in TKV (measured in mL by MRI) divided by each participant's years of participation for all participants was calculated using MMRM analysis in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing annualized slope of TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.</description>
        <time_frame>Study Baseline (Prior to Day 1 in Study 156-08-271) to Month 24 in this study (Study 156-08-271)</time_frame>
        <population>The Efficacy Sample consisted of all enrolled participants who took at least 1 dose of study drug and completed 3 years of study drug treatment in previous Study 156-04-251. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan)</title>
            <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with tolvaptan in Study 156-04-251.</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo)</title>
            <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with placebo in Study 156-04-251.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Slope of Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in Study 156-08-271</title>
          <description>Annualized slope of TKV is a measure of renal function and disease progression in ADPKD participants. The annualized slope is calculated as percentage of growth in TKV (measured in mL by MRI) divided by each participant's years of participation for all participants was calculated using MMRM analysis in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing annualized slope of TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.</description>
          <population>The Efficacy Sample consisted of all enrolled participants who took at least 1 dose of study drug and completed 3 years of study drug treatment in previous Study 156-04-251. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>percent change in TKV/participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
                <count group_id="O2" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.164"/>
                    <measurement group_id="O2" value="4.960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority for early-treatment and delayed-treatment groups.</non_inferiority_desc>
            <p_value>0.0462</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of geometric means (final values)</param_type>
            <param_value>1.011</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.000</ci_lower_limit>
            <ci_upper_limit>1.023</ci_upper_limit>
            <other_analysis_desc>Derived from testing interaction of time and treatment using linear mixed model in which intercept and time are treated as random effects.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Slope of eGFR (CKD-EPI) for Study 156-04-251 Participants Enrolled in Study 156-08-271</title>
        <description>Annualized slope of eGFR (CKD-EPI) is a measure of renal function and disease progression in ADPKD participants. The annualized slope of eGFR (CKD-EPI) (divided by each participant's years of participation) for all participants was calculated using MMRM analysis in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). eGFR was calculated using the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula. This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.</description>
        <time_frame>Study Baseline (Prior to Day 1 in Study 156-08-271) to Month 24 (Study 156-08-271)</time_frame>
        <population>The Efficacy Sample consisted of all enrolled participants who took at least 1 dose of study drug and completed 3 years of study drug treatment in previous Study 156-04-251. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan)</title>
            <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with tolvaptan in Study 156-04-251.</description>
          </group>
          <group group_id="O2">
            <title>Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo)</title>
            <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with placebo in Study 156-04-251.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Slope of eGFR (CKD-EPI) for Study 156-04-251 Participants Enrolled in Study 156-08-271</title>
          <description>Annualized slope of eGFR (CKD-EPI) is a measure of renal function and disease progression in ADPKD participants. The annualized slope of eGFR (CKD-EPI) (divided by each participant's years of participation) for all participants was calculated using MMRM analysis in participants continuing from previous study (156-04-251) at Month 24 of this study (156-08-271) comparing change in TKV for the early-treated (those previously treated with tolvaptan) to delayed-treated (those previously treated with placebo). eGFR was calculated using the Chronic Kidney Disease-Epidemiology (CKD-EPI) formula. This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251, as pre-specified in the protocol.</description>
          <population>The Efficacy Sample consisted of all enrolled participants who took at least 1 dose of study drug and completed 3 years of study drug treatment in previous Study 156-04-251. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>ml/min/1.73m^2/participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="549"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.255"/>
                    <measurement group_id="O2" value="-3.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority for early-treatment and delayed-treatment groups.</non_inferiority_desc>
            <p_value>0.7259</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of geometric means (final values)</param_type>
            <param_value>-0.113</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.746</ci_lower_limit>
            <ci_upper_limit>0.520</ci_upper_limit>
            <other_analysis_desc>Derived from testing interaction of time and treatment using linear mixed model in which intercept and time are treated as random effects.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized TKV Slope for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271</title>
        <description>Annualized slope of TKV is a measure of renal function and disease progression in ADPKD participants. The annualized slope is calculated as percentage of growth in TKV (measured in mL by MRI) divided by each participant's years of participation, using MMRM analysis to compare annualized slope of TKV for the participants who received placebo in previous study (156-04-251) to annualized slope of TKV for the same participants who received tolvaptan in this study (156-08-271). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251 and who received placebo in the previous study, as pre-specified in the protocol.</description>
        <time_frame>Tolvaptan, Delayed Treated: Baseline to Month 24 in Study 156-08-271; Placebo: Baseline to Month 36 in Study 156-04-251</time_frame>
        <population>The Efficacy Sample consisted of all enrolled participants who took at least 1 dose of study drug and completed 3 years of study drug treatment in previous Study 156-04-251. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolvaptan, Delayed Treated (In Study 156-08-271)</title>
            <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with placebo in Study 156-04-251.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (In Study 156-04-251)</title>
            <description>Participants were treated with placebo in the previous Study 156-04-251.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized TKV Slope for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271</title>
          <description>Annualized slope of TKV is a measure of renal function and disease progression in ADPKD participants. The annualized slope is calculated as percentage of growth in TKV (measured in mL by MRI) divided by each participant's years of participation, using MMRM analysis to compare annualized slope of TKV for the participants who received placebo in previous study (156-04-251) to annualized slope of TKV for the same participants who received tolvaptan in this study (156-08-271). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251 and who received placebo in the previous study, as pre-specified in the protocol.</description>
          <population>The Efficacy Sample consisted of all enrolled participants who took at least 1 dose of study drug and completed 3 years of study drug treatment in previous Study 156-04-251. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>percent change in TKV/participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.779"/>
                    <measurement group_id="O2" value="5.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1080</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of geometric means (final values)</param_type>
            <param_value>0.992</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.982</ci_lower_limit>
            <ci_upper_limit>1.002</ci_upper_limit>
            <other_analysis_desc>Derived from linear mixed model with terms of participant, treatment, time, interaction of treatment and time, interaction of participant and time, and baseline for intra-participant comparison between 251 and 271. Time and intercept are treated as random effects.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Slope of Renal Function (eGFRCKD-EPI) for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271</title>
        <description>Annualized slope of eGFR (CKD-EPI) is a measure of renal function and disease progression in ADPKD participants. The annualized slope of eGFR (calculated using CKD-EPI formula) divided by each participant's years of participation, using MMRM analysis to compare annualized slope of eGFR (CKD-EPI) for the participants who received placebo in previous study (156-04-251) to the annualized slope of eGFR (CKD-EPI) for the same participants who received tolvaptan in this study (156-08-271). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251 who received placebo in previous study and received tolvaptan in this study, as pre-specified in the protocol.</description>
        <time_frame>Tolvaptan, Delayed Treated: Baseline to Month 24 in Study 156-08-271; Placebo: Baseline to Month 36 in Study 156-04-251</time_frame>
        <population>The Efficacy Sample consisted of all enrolled participants who took at least 1 dose of study drug and completed 3 years of study drug treatment in previous Study 156-04-251. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tolvaptan, Delayed Treated (In Study 156-08-271)</title>
            <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with placebo in Study 156-04-251.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (In Study 156-04-251)</title>
            <description>Participants were treated with placebo in the previous Study 156-04-251.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Slope of Renal Function (eGFRCKD-EPI) for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271</title>
          <description>Annualized slope of eGFR (CKD-EPI) is a measure of renal function and disease progression in ADPKD participants. The annualized slope of eGFR (calculated using CKD-EPI formula) divided by each participant's years of participation, using MMRM analysis to compare annualized slope of eGFR (CKD-EPI) for the participants who received placebo in previous study (156-04-251) to the annualized slope of eGFR (CKD-EPI) for the same participants who received tolvaptan in this study (156-08-271). This outcome measure was analyzed only in the participants enrolled from the previous study - 156-04-251 who received placebo in previous study and received tolvaptan in this study, as pre-specified in the protocol.</description>
          <population>The Efficacy Sample consisted of all enrolled participants who took at least 1 dose of study drug and completed 3 years of study drug treatment in previous Study 156-04-251. Overall number of participants analyzed signifies the number of participants who were evaluable for this outcome measure.</population>
          <units>ml/min/1.73m^2/participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.211"/>
                    <measurement group_id="O2" value="-3.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2265</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio of geometric means (final values)</param_type>
            <param_value>0.361</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.224</ci_lower_limit>
            <ci_upper_limit>0.946</ci_upper_limit>
            <other_analysis_desc>Derived from linear mixed model with terms of participant, treatment, time, interaction of treatment and time, interaction of participant and time, and baseline for intra-participant comparison between 251 and 271. Time and intercept are treated as random effects.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the signing of the informed consent form until the end of the study regardless of whether the participants were on or off active study medication (Up to approximately 5 years)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated)</title>
          <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with tolvaptan in previous Study 156-04-251, hence called as Early Treated.</description>
        </group>
        <group group_id="E2">
          <title>Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated)</title>
          <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with placebo in the previous Study 156-04-251, hence called as Delayed Treated.</description>
        </group>
        <group group_id="E3">
          <title>Tolvaptan (From Other Studies: Tolvaptan, Early Treated)</title>
          <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with tolvaptan in other studies (156-04-250, 156-06-260, 156-09-284, 156-09-285, and 156-09-290), hence called as Early Treated.</description>
        </group>
        <group group_id="E4">
          <title>Tolvaptan (From Other Studies: Placebo, Delayed Treated)</title>
          <description>Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 mg [AM]/15 mg [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily up to Month 24. Participants were previously treated with placebo in other studies (156-04-250, 156-06-260, 156-09-284, 156-09-285, and 156-09-290), hence called as Delayed Treated.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated Idioventricular Rhythm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Prinzmetal Angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinus Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital Cystic Kidney Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastritis Erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ileus Paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Intestinal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Large Intestine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Localised Intraabdominal Fluid Collection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pancreatitis Necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Systemic Inflammatory Response Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Biliary Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Drug-Induced Liver Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Hepatic Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hepatic Cyst</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hepatic Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hepatocellular Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Portal Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to Arthropod Sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Atopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Catheter Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Chronic Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhoea Infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Genital Herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Kidney Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pharyngitis Streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Renal Cyst Infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ureteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Viral Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Expired Product Administered</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gun Shot Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Incisional Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ligament Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Meniscus Injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Renal Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Shunt Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Lactate Dehydrogenase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gamma-Glutamyltransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Glomerular Filtration Rate Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Smear Cervix Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vasopressin Challenge Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Foot Deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Loose Body In Joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cervix Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cholesterin Granuloma Of Middle Ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Endometrial Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Stromal Tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Intraductal Proliferative Breast Lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Plasma Cell Myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Testis Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Carotid Artery Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Carotid Artery Dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cerebral Atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Essential Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Intracranial Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lumbar Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Occipital Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gestational Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Chronic Kidney Disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Renal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Renal Cyst Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Renal Cyst Ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Renal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Renal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urine Flow Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Breast Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Postmenopausal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Lung Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasal Septum Deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pharyngeal Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Aortic Dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Arterial Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Peripheral Venous Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Subclavian Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="528" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="310" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="175" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="261" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetitie</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vitamin D Deficiency</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="231" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="111" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Renal Cyst Ruptured</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Renal Pain</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="557"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="314"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial did not meet its primary endpoint as both groups showed similar decreases in the rate of TKV growth due in part to unforeseen limitations in the trial design. However, early-treatment resulted in cumulative improvements in renal function.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Global Clinical Development</name_or_title>
      <organization>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</organization>
      <phone>+1-609-524-6788</phone>
      <email>clinicaltransparency@otsuka-us.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

